Top congressional Democrats are pressing pharmaceutical companies to immediately release the unredacted terms of their “most favored nation” pricing agreements with the Trump administration, according to a source familiar with the effort. The demand signals that the incoming Democratic majority intends to aggressively scrutinize the deals struck by the outgoing administration.
The request was sent by the lawmakers poised to lead health policy committees next year: Rep. Frank Pallone Jr. (D-N.J.) of the Energy and Commerce Committee, Rep. Richard Neal (D-Mass.) of Ways and Means, Rep. Bobby Scott (D-Va.) of Education and Workforce, and Sen. Ron Wyden (D-Ore.) of the Senate Finance Committee. Their joint action represents a notable escalation from a March letter asking for copies of the agreements, which the administration ignored.
Under the most-favored-nation model, manufacturers pledged not to charge Medicaid more than the lowest price they offer in other developed countries for certain drugs. The deals have been a centerpiece of President Trump’s health agenda, with officials touting billions in savings for American taxpayers.
But Democrats have long been skeptical of the arrangements, noting that both administration officials and company executives have cited confidentiality in refusing to disclose details. Lawmakers now want to know exactly what drug companies received in exchange for agreeing to lower Medicaid prices, and whether the promised savings are real.
“The American people deserve to know how their tax dollars are being spent and whether these deals actually deliver the savings claimed,” said a Democratic aide, speaking on condition of anonymity to discuss internal strategy. The aide added that the committee leaders expect full cooperation.
If companies cannot provide the documents—due to non-disclosure agreements with the White House or other constraints—they have been instructed to meet with lawmakers within two weeks to explain how they will fulfill the request, the source said.
Once Democrats assume control of the House in January, they will have the power to issue subpoenas, compel testimony, and hold hearings on the Trump administration’s policies. This move is part of a broader oversight push that includes rural health funding and other executive actions.
The escalation also comes amid heightened political tensions, with Trump questioning the integrity of recent elections and Republicans facing internal divisions over how to handle the president’s legacy. Democrats are positioning themselves to hold the administration accountable on multiple fronts.
Pharmaceutical companies have not yet publicly responded to the request. Some legal experts note that the most-favored-nation agreements may contain confidentiality clauses that could complicate disclosure, but Democrats argue that public interest outweighs such concerns.
“These are public programs funded by taxpayers,” the aide said. “There is no legitimate reason to keep the details secret.”
The push is likely to be one of the first major oversight battles of the new Congress, setting the tone for Democratic investigations into the Trump administration’s health policies.
